#generalised pustular psoriasis market share

[kritikarehani]

Generalized Pustular Psoriasis (GPP) Market Insights, Epidemiology and Market Forecast - 2028

DelveInsight’s Generalized Pustular Psoriasis (GPP) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Generalized Pustular Psoriasis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Generalized Pustular Psoriasis from 2017 to 2028 segmented by the seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Geography Covered

The United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2017-2028 Generalized Pustular Psoriasis (GPP) – Disease Understanding and Treatment Algorithm Generalized Pustular Psoriasis (GPP) is a subtype of pustular psoriasis characterized by painful and occasionally disfiguring cutaneous manifestations with sepsis-like systemic symptoms. GPP has been associated with abnormalities in the cytokine (messenger protein) interleukin -36-receptor-antagonist signaling. This is due to recessive IL36RN gene mutations systemic symptoms and systemic upset. GPP is characterized by recurrent acute flares and these flares may result in:  headache, rapid pulse rate, loss of appetite and nausea and leg swelling. The DelveInsight’s Generalized Pustular Psoriasis market report gives the thorough understanding of the Generalized Pustular Psoriasis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for GPP in the US, Europe, and Japan.

Generalized Pustular Psoriasis Epidemiology

The GPP epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight’s report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Diagnosed Prevalence Population, Gender Specific Diagnosed Prevalence Population, Age Specific Diagnosed Prevalence Population and Severity Specific Diagnosed Prevalence Population] scenario of Generalized Pustular Psoriasis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2028. As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males. According to DelveInsight, total diagnosed prevalent Population of GPP in the 7MM was assessed to be more than 14,000 in 2017, which is expected to increase at a CAGR of XX% for the study period i.e. 2017-2028. Our estimates suggests highest diagnosed prevalence of GPP in the United States with close to 6,000 cases in 2017. Furthermore, among the EU-5 countries, France had the highest diagnosed prevalent population of GPP, followed by Germany and the United Kingdom. On the other hand, Spain was assessed with the lowest diagnosed prevalent population. DelveInsight’s estimations showed that Japan had 2,602 prevalent cases for GPP in 2017. Assessments as per DelveInsight’s analysts showed that the severe cases of GPP accounted for majority of the diagnosed prevalent population across 7MM countries, followed by the number of patients with moderate symptoms. However, the least number of cases were assessed for patient with mild symptoms. Generalized Pustular Psoriasis (GPP)– Drug Chapters This segment of the GPP report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Tremfya (Guselkumab, CNTO1959) is a fully human anti-interleukin (IL)-23 HuCAL monoclonal antibody being marketed by Janssen for Generalized Pustular Psoriasis in Japan. Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. Guselkumab is being developed by HuCAL antibody library technology platform under a licensing agreement of Janssen Pharmaceuticals with MorphoSys. Guselkumab is currently marketed in Japan for the treatment of Generalized Pustular Psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. However, it is not approved in the United States and Europe for pustular psoriasis and erythrodermic psoriasis.

COSENTYX (Secukinumab) is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. Secukinumab inhibits the release of proinflammatory cytokines and chemokines. It is being marketed by Novartis Pharmaceuticals for Generalized Pustular Psoriasis disease.

Lumicef (Brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist being marketed by Kyowa Hakko Kirin in Japan for Generalized Pustular Psoriasis, pustular psoriasis, and erythrodermic psoriasis. It is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. In October 2010, Kyowa Hakko Kirin licensed from Kirin-Amgen exclusive rights to develop and commercialize brodalumab in Japan and certain other Asian countries.

Skyrizi (Risankizumab) is a humanized IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. It is being marketed by Abbvie. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of Skyrizi globally. Skyrizi is currently under review with the U.S. Food and Drug Administration (FDA) and the company expects a regulatory decision in the first half of 2019.

HUMIRA is a tumor necrosis factor (TNF) blocker being marketed by AbbVie/ Eisai for generalized pustular psoriasis and is available as a subcutaneous Injection. In plaque psoriasis, treatment with HUMIRA may reduce the epidermal thickness and infiltration of inflammatory cells.

Taltz (Ixekizumab) is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor and it inhibits the release of proinflammatory cytokines and chemokines. It is being marketed by Eli Lilly & company for Pustular Psoriasis in Japan.

REMICADE (Infliximab) is a tumor necrosis factor (TNF) blocker being marketed by Mitsubishi Tanabe Pharma in Japan for Generalized Pustular Psoriasis. It neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. In January 2010 REMICADE received the approval from Ministry of Health, Labour and Welfare, Japan for additional indications including pustular psoriasis, Erythrodermic Psoriasis.

Generalized Pustular Psoriasis Market Outlook

The Generalized Pustular Psoriasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. The market size of GPP in the seven major markets is expected to grow at a CAGR of 10.16% for the study period (2017-2028). The current therapeutic landscape of GPP in the United States is driven by supportive therapies (topical therapies, systemic therapies, biologics and phototherapy). In EU-5 countries, for GPP, the market is same as that of the US, with prescriptions for supportive therapies, due to lack of approved treatment regimens, and together accounted for nearly USD 20.21 million in 2017. In contrast to the US and EU-5 countries, the current therapeutic landscape of GPP in Japan is driven by a number of approved therapies, along with supportive treatment regimens. A modest increase in market size of currently prescribed therapies has been witnessed from 2017 until the launch of emerging therapies in respective countries. The market share is expected to decline post that for current therapies, across the 7MM, owing to the increasing demand for targeted therapies to treat GPP. Among the current treatment regimens, biologics occupy the highest number of prescriptions in the treatment market of GPP. Moreover, combination therapies remain the mainstay in the treatment of GPP, irrespective of the severity of the disease. Generalized Pustular Psoriasis (GPP)– Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. The dynamics of GPP market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019-2028. With this, several companies have shifted their focus toward this therapeutic area, and two of the therapies are expected to enter the treatment market of GPP during our forecast period, namely BI 655130 (Boehringer Ingelheim) and ANB019 (AnaptysBio). Spesolimab (BI655130) is a new biological entity and first-in-class, intravenous, IL-36 receptor monoclonal antibody being in development for GPP Psoriasis by Boehringer Ingelheim. The drug candidate is the second compound being developed under the company’s immunology division (after risankizumab) and has already shown strong efficacy in early clinical testing with a single dose in patients affected by GPP. The company intends to initiate a Phase III study of BI655130 in Generalized Pustular Psoriasis from May 2019. ANB019 is an interleukin-36-receptor inhibitor monoclonal antibody being in Phase II stage of development by AnaptysBio for GPP. The drug candidate is the company’s most advanced wholly-owned antibody programs which it initially developing as a potentially first-in-class therapy for patients suffering from GPP and palmoplantar pustulosis. AnaptysBio had already demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties of ANB019 in Phase I clinical trial in healthy volunteers. The company has subsequently initiated a 10-patient open-label, multi-dose, single-arm Phase II trial of ANB019 in GPP patients, also referred to as the GALLOP trial, where top-line data are anticipated in mid-2019. Generalized Pustular Psoriasis (GPP) Report Insights

Generalized Pustular Psoriasis Patient Population

Generalized Pustular Psoriasis Therapeutic Approaches

Generalized Pustular Psoriasis Pipeline Analysis

Generalized Pustular Psoriasis Market Size and Generalized Pustular Psoriasis Market Trends

Generalized Pustular Psoriasis Market Opportunities

Impact of upcoming Generalized Pustular Psoriasis Therapies

Generalized Pustular Psoriasis (GPP) Report Key Strengths

10 Years Generalized Pustular Psoriasis Forecast

Generalized Pustular Psoriasis 7MM Coverage

Generalized Pustular Psoriasis Epidemiology Segmentation

Key Cross Competition

Generalized Pustular Psoriasis Market Size

Generalized Pustular Psoriasis Drugs Uptake

Generalized Pustular Psoriasis (GPP) Report Assessment

Generalized Pustular Psoriasis Pipeline Product Profiles

Generalized Pustular Psoriasis Key Products and Generalized Pustular Psoriasis Key Players

Generalized Pustular Psoriasis Market Drivers and Generalized Pustular Psoriasis Market Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Generalized Pustular Psoriasis market

Organize sales and marketing efforts by identifying the best opportunities for Generalized Pustular Psoriasis market

To understand the future market competition in the GPP market.